Proactive Investors - Futura Medical (LON:FUM)'s upbeat commentary ahead of its annual meeting garnered a muted response.
But broker Liberum believes the company's potential is being significantly underrated by the market.
It sees scope for forecast upgrades this year but is leaving its spreadsheets unchanged until it has more details on Futura's operational performance and the take-up of Eroxon, its gel for erectile dysfunction.
Liberum repeated its 131p target (current price 36.4p) and said it expects "plenty of catalysts over the next few months".
"Specifically, we think that Futura starting to generate meaningful EBITDA will remove the final barrier to broader institutional ownership," said Liberum.
Earlier Futura said it has successfully launched its sexual health product in ten countries, including key European markets such as France, Italy, and Spain, during the first half of 2024.
These debuts have gone according to plan, and the company's revenues are on track with market expectations for the fiscal year 2024, chairman Jeff Needham confirmed in comments ahead of the company's annual meeting.
More launches are anticipated in the second half in Europe and other parts of the world. An update on trading for 2024 will be provided during the company's interim results in September.
Futura Medical is also preparing for the US launch of Eroxon in collaboration with Haleon PLC (LON:HLN), the global consumer healthcare company that owns Durex. Haleon reiterated its plan to launch Eroxon in the States within the next 12 months during its first quarter trading update in May.